Tertiary lymphoid structures predict the neoadjuvant chemoimmunotherapy response of stage III non-small cell lung cancer

Ren, Guibing; Department of Oncology, Integrative Medical Center, Tianjin University/Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Qu, Yajing; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Li, Hainan; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China; Tianjin’s Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Tia, Li, Zhihong; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Gao, Yanyan; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Shi, Xiaoxiong; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Meng, Xiaoru; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Xu, Pengpeng; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Hu, Weihao; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Liu, Ningbo; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China; Tianjin’s Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Ti, Huo, Lili; Department of Oncology, Characteristic Medical Center of Chinese People’s Armed Police Force, Tianjin, China, Luo, Jing; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China; Tianjin’s Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Tian